Sawai
Sawai Pharmaceutical Co., Ltd. is a Japanese manufacturer based in Osaka that specializes in producing a variety of pharmaceutical products. Established in response to medicine shortages during and after the Second World War, the company has played a vital role in addressing local healthcare needs. Sawai offers a wide range of prescription drugs in multiple formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, and syrups. Their product portfolio covers various therapeutic areas, such as cardiovascular health, gastrointestinal issues, chemotherapeutics, vitamins, and anti-cancer treatments, reflecting the company's commitment to improving public health through accessible medication.
4 past transactions
Meta Osaka
Seed Round in 2024
Meta Osaka is a company specializing in metaverse-related services. It offers a range of solutions, including advertising, animation, 3D modeling, event planning, and management, as well as consulting services. The company leverages metaverse technologies to help clients, including businesses and local governments, address regional issues and enhance their operations. It achieves this by running 'digital twin' events that blend real-world events with metaverse elements, enabling clients to explore and utilize the metaverse to tackle their specific challenges.
Neurolief
Corporate Round in 2023
Neurolief is a neuromodulation company dedicated to bringing relief to patients suffering from mental health and neurological disorders. The company consists of highly experienced professionals with a proven track record in neuroscience, neuromodulation technology, and the neurotech industry. Neurolief has developed a disruptive platform technology, the world's first and only non-invasive, multi-channel brain neuromodulation system designed to concurrently neuromodulate major neural pathways in the head and thereby affect brain regions involved in the control and modulation of mood and pain.
Susmed
Corporate Round in 2020
Susmed develops therapeutic smartphone applications and digital solutions that streamline clinical trials. Its product portfolio includes apps for conditions such as insomnia, breast cancer, and kidney disease. The company also offers the Susumed System, a blockchain‑based platform that enhances the reliability of clinical trial data while reducing personnel and cost requirements. Susmed’s operations are organized into two segments: the DTx Product Business, focused on therapeutic app development, and the DTx Platform Business, which provides a general‑purpose clinical trial platform.
Upsher Smith Laboratories
Acquisition in 2017
Upsher Smith Laboratories a partner in healthcare, striving to deliver high-value, high-quality therapies and solutions that measurably improve individuals’ lives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.